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Aims N-terminal-pro-B-type-natriuretic-peptide (NT-pro-BNP) concentrations are altered in renal failure. This study
examined the effect of baseline and change from baseline NT-pro-BNP on cardiovascular outcome and mortality
in haemodialysis patients.
Methods
and results
On the basis of the German Diabetes and Dialysis Study, which evaluated atorvastatin in 1255 type 2 diabetes mel-
litus (T2DM) haemodialysis patients (median follow-up 4 years), the impact of NT-pro-BNP on pre-speciﬁed, adju-
dicated endpoints was investigated: sudden death (SD; n ¼ 160), stroke (n ¼ 99), myocardial infarction (MI; n ¼ 200),
cardiovascular events (CVEs: cardiac death, MI, stroke; n ¼ 465), all-cause mortality (n ¼ 612). Patients with baseline
NT-pro-BNP  9252 pg/mL (fourth quartile) exhibited a more than four-fold risk of stroke [hazard ratio (HR) 4.1;
95% conﬁdence interval (CI) 2.0–8.4] and a more than two-fold risk of SD (HR 2.0; 95% CI 1.2–3.3), CVE (HR
2.0; 95% CI 1.5–2.7), and mortality (HR 2.1; 95% CI 1.6–2.7) compared with patients with baseline NT-
pro-BNP   1433 pg/mL (ﬁrst quartile). Change in NT-pro-BNP was strongly associated with SD, CVE, and mortality.
Doubling of NT-pro-BNP increased the risk of death by 46% (95% CI 1.1–2.0). Neither baseline nor change in NT-
pro-BNP was signiﬁcantly associated with MI.
Conclusion Increasing NT-pro-BNP is a risk factor for SD, CVE, and mortality in haemodialysis patients with T2DM. Whether
NT-pro-BNP-guided treatment improves outcome needs to be evaluated prospectively.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Brain natriuretic peptide (BNP) and its counterpart N-terminal-
pro-B-type-natriuretic-peptide (NT-pro-BNP) are associated
with morbidity and mortality in a wide range of patients.
1–4
This has stimulated interest about the role of NT-pro-BNP in
renal patients. In chronic kidney disease, NT-pro-BNP was
associated with coronary artery disease (CAD) and left ventricu-
lar hypertrophy.
5 In peritoneal dialysis patients, NT-pro-BNP was
related to left ventricular dysfunction, cardiovascular events
(CVEs), and mortality.
6,7 Finally, in a cohort of 399 haemodialysis
patients, NT-pro-BNP was associated with 2 year all-cause death
8
and, in a smaller cohort, with 3 year cardiac morbidity and
mortality.
9
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doi:10.1093/eurheartj/ehn278Up to now, the association of baseline NT-pro-BNP with
sudden death (SD), stroke, and myocardial infarction (MI) has
not been evaluated in renal patients. Furthermore, the effect of a
longitudinal change in NT-pro-BNP on outcome has not been
investigated before. Therefore, we assessed the effect of baseline
and change from baseline NT-pro-BNP on SD, stroke, MI, CVE,
and all-cause mortality by performing post hoc analyses of the
German Diabetes Dialysis Study [4D-Study (Die Deutsche Dia-
betes Dialyse Studie)],
10 which evaluated atorvastatin in 1255
patients with type 2 diabetes mellitus (T2DM) on maintenance
haemodialysis treatment.
Methods
Study design and participants
The 4D-Study methodology has previously been reported.
11 Brieﬂy,
the 4D-Study was a randomized trial including 1255 patients with
T2DM, 18–80 years, and previous duration of haemodialysis of ,2
years. Between March 1998 and October 2002, patients were
recruited in 178 dialysis units throughout Germany. After a period
of 4 weeks, patients were randomly assigned to double-blind treatment
with either 20 mg of atorvastatin (n ¼ 619) or placebo (n ¼ 636)
once daily. Study visits took place three times before randomization
(visit 1–3), at randomization (visit 4), and at four weeks (visit 5) and
every six months (visit 6 etc.) after randomization. At each follow-up
until March 2004, a blood sample was taken and information was
recorded about any suspected endpoint or serious adverse event.
The primary study endpoint of the 4D-Study was a composite of
death from cardiac causes, MI, and stroke, whichever occurred ﬁrst.
Death from any cause, SD, stroke, and MI (fatal and non-fatal MI)
were secondary study endpoints. 4D-Study endpoints were centrally
adjudicated by three members of the endpoint committee blinded to
study treatment and according to pre-deﬁned criteria.
10
For the present analysis, the combined cardiovascular endpoint
(cardiac death, MI, stroke), all-cause death, SD, stroke, and MI were
all chosen to be separate outcome measures and were based on the
primary judgement of the endpoint committee during the 4D-Study.
NT-pro-BNP was measured in blood samples taken at study visit 3
(1 week before randomization) and visit 6 (6 months after randomiz-
ation). If there was no sample available at visit 6 (n ¼ 20), a sample
taken at the following study visit was chosen (visit 7: n ¼ 19; visit 11:
n ¼ 1). One of those 20 patients experienced a non-fatal stroke
before visit 7 and was therefore censored for analysis.
Laboratory procedures
All laboratory measurements of the 4D-Study including NT-pro-BNP
were performed at the Department of Clinical Chemistry, University
of Freiburg, Germany. Measurements of NT-pro-BNP were performed
by electrochemiluminescence immunoassay on an E 170 analyser
(Roche Diagnostics, Mannheim, Germany). Inter-assay coefﬁcients of
variance were ,5%. Blood samples were taken before the start of
dialysis and administration of drugs.
Statistical analysis
Baseline patient characteristics are presented according to baseline
NT-pro-BNP quartiles. Continuous variables were expressed with
mean and standard deviation, and categorical variables were expressed
with absolute and relative frequencies. The effect of NT-pro-BNP
(baseline and change from baseline) on outcome was assessed by
Kaplan–Meier estimates for incidences of the pre-speciﬁed endpoints
and by relative risks derived from Cox regression analyses, i.e. hazard
ratios (HRs) and corresponding 95% conﬁdence intervals. The Cox
regression analyses were adjusted for the confounders of gender,
age, atorvastatin treatment, phosphate, low-density lipoprotein, hae-
moglobin, glycated haemoglobin, albumin, smoking, systolic/diastolic
blood pressure, body mass index, ultraﬁltration volume, duration of
dialysis, arterio-venous (AV) ﬁstula, history of stroke or transitory
ischaemic attack, CAD (e.g. MI, coronary artery bypass grafting, percu-
taneous coronary intervention, or angiographically documented CAD),
peripheral vascular disease, and congestive heart failure (CHF; predo-
minantly New York Heart Association class II).
In detail, the following analyses were performed. First, the associ-
ation of baseline NT-pro-BNP with the pre-deﬁned outcome
measures of SD, stroke, MI, CVE, and mortality was analysed, both
as a continuous variable (logarithmically transformed because values
were not normally distributed and the linearity assumption was satis-
ﬁed for the log-transformed values) and as a categorical variable (base-
line NT-pro-BNP quartiles). Second, the association between change
in NT-pro-BNP and outcome was evaluated: as a continuous variable
(logarithmically transformed ratio of post-baseline/baseline NT-pro-
BNP) and as a categorical variable (less than 210%, 210 up to
þ10%, .10 up to 100%, and .100% change in NT-pro-BNP).
Third, since baseline levels might affect this association, additional ana-
lyses regarding the effect of the change in NT-pro-BNP on outcome
were done in subgroups of patients with baseline NT-pro-BNP
values less than or equal to and greater than the median. Finally, we
performed subgroup analyses regarding co-morbidity (patients with
and without history of CAD, and with and without history of CHF)
and determined the association of baseline and change in NT-pro-BNP
with total mortality (other outcomes had no adequate power in sub-
groups). In general, to compare NT-pro-BNP between the atorvastatin
and placebo groups, the Wilcoxon rank-sum test was used, whereas
the Wilcoxon signed-rank test was applied to compare baseline with
post-baseline NT-pro-BNP within groups. All P-values are reported
two-sided. In the models assessing the effect of the change in
NT-pro-BNP on outcome, patients experiencing an endpoint before
the second NT-pro-BNP measurement were used as censored at
this time point (22 patients experienced a CVE, eight a stroke, and
14 a non-fatal MI prior to the second measurement). Analyses were
done using SAS version 8.2.
Results
Of 1255 patients taking part in the 4D-Study, 1249 had a baseline
and 1205 had a post-baseline NT-pro-BNP measurement, with
1203 patients having both. In total, 633 placebo and 616 atorvasta-
tin samples at baseline and 606 placebo and 599 atorvastatin
samples after a median of 182 days (interquartile range 177–185
days) were analysed. The mean follow-up-period was 3.96 years
(median 4.0 years) on atorvastatin and 3.91 years (median 4.08
years) on placebo. During follow-up, 612 patients died (160 of
SD). Furthermore, 465 patients reached the composite cardiovas-
cular endpoint (CVE) (cardiac death, non-fatal MI, stroke), with MI
and stroke occurring in 200 and 99 patients, respectively.
Median baseline NT-pro-BNP was high (3361 pg/mL). During
follow-up, NT-pro-BNP increased signiﬁcantly (median increase
of 219 pg/mL, P , 0.001). No signiﬁcant difference between the
atorvastatin and placebo group with respect to baseline, post-
baseline, and change from baseline NT-pro-BNP was detected.
Patients’ baseline characteristics are shown in Table 1.
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Table 1 Baseline patient characteristics according to quartiles of baseline N-terminal-pro-B-type-natriuretic-peptide
Variable NT-pro-BNP (pg/mL)
Quartile 1  1433
(n 5 313)
Quartile 2 1434–3361
(n 5 312)
Quartile 3 3362–9251
(n 5 312)
Quartile 4  9252
(n 5 312)
Age, years 64.8+8.7 65.7+8.4 66.5+7.6 65.8+8.2
Gender male,% (n) 54 (170) 55 (171) 52 (161) 55 (170)
Ever smoking,% (n) 37 (116) 42 (130) 40 (125) 43 (134)
Body mass index, kg/m
2 28.9+5.2 28.2+4.5 27.1+4.6 26.0+4.4
Systolic blood pressure,
mmHg
143+21 144+22 147+23 149+22
Diastolic blood pressure,
mmHg
75+11 75+10 76+11 77+11
Timereceiving dialysis,months 8.0+6.8 8.4+7.2 8.2+6.8 8.5+6.7
Ultraﬁltration volume, kg 1.97+1.19 2.30+1.16 2.33+1.18 2.42+1.22
Shunt,% (n) 94 (294) 95 (297) 94 (294) 90 (279)
History
a
Arrhythmia,% (n) 11 (33) 13 (39) 25 (77) 27 (85)
MI, CABG, PCI, or CHD,%
(n)
21 (67) 27 (83) 31 (98) 38 (117)
CHF
b,%( n) 27 (84) 30 (93) 37 (115) 48 (149)
Stroke/TIA,% (n) 18 (57) 17 (53) 19 (60) 17 (52)
Peripheral vascular
disease,% (n)
36 (113) 46 (145) 41 (128) 54 (169)
Haemoglobin, g/dL 11.1+1.4 10.9+1.2 10.9+1.3 10.6+1.4
Glycated haemoglobin, % 6.79+1.25 6.67+1.27 6.75+1.26 6.67+1.26
Phosphate, mg/L 1.86+0.43 1.99+0.52 1.95+0.55 2.00+0.57
Albumin, g/dL 3.87+0.27 3.84+0.28 3.81+0.31 3.76+0.33
LDL cholesterol, mg/dL 127+30 125+31 126+30 125+29
Data are given as mean+standard deviation. To convert haemoglobin values to mmol/L, multiply by 0.6206; to convert values for phosphate to mmol/L, multiply by 0.32; to
convert values for LDL cholesterol to mmol/L, multiply by 0.02566. CABG, coronary artery bypass grafting surgery; PCI, percutaneous coronary intervention; CHD, coronary
heart disease, documented by coronary angiography; TIA, transitory ischaemic attack.
aTypes of disease and intervention are not mutually exclusive.
bPredominantly New York Heart Association II.
Figure 1 Kaplan–Meier estimates for time to sudden death, stroke, and myocardial infarction in subgroups of patients according to quartiles
of baseline N-terminal-pro-B-type-natriuretic-peptide (Q1, Quartile 1: N-terminal-pro-B-type-natriuretic-peptide   1433 pg/mL; Q2, quartile
2: N-terminal-pro-B-type-natriuretic-peptide 1434–3361 pg/mL; Q3, quartile 3: N-terminal-pro-B-type-natriuretic-peptide 3362–9251 pg/
mL; Q4, quartile 4: N-terminal-pro-B-type-natriuretic-peptide   9252 pg/mL).
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Absolute risks
Overall, the absolute mortality risks were high and increasing over
quartiles of baseline NT-pro-BNP. After 4 years of follow-up, the
cumulative incidences of all-cause mortality were 0.323 in the
ﬁrst quartile, 0.427 in the second quartile, 0.545 in the third quar-
tile, and 0.677 in the highest quartile of baseline NT-pro-BNP.
Regarding the change in NT-pro-BNP, mortality risks increased
with rising NT-pro-BNP levels. The 4 year cumulative incidences of
death were 0.420 in patients with decreasing NT-pro-BNP, 0.424
in patients with stable levels, and 0.481 in patients with an increase
of NT-pro-BNP .10 and  100%. The highest risk of 0.654 was
seen in patients with more than a doubling in NT-pro-BNP levels.
Relative risks
Baseline NT-pro-BNP was signiﬁcantly associated with the risk of
SD,stroke,CVEs,andmortality.Perunitincreaseinlog-transformed
baseline NT-pro-BNP, the relative risks of experiencing these end-
points increased, as being reﬂected by the adjusted HRs: HRSD 1.28
(1.12–1.47), HRstroke 1.39 (1.17–1.65), HRCVE 1.24 (1.15–1.34),
HRmortality 1.27 (1.18–1.36). With regard to MI, no association
was seen [HRMI 1.08 (0.96–1.22)]. One unit increase in log-
transformedNT-pro-BNPwasequaltoa2.72-foldincreaseinabsol-
ute values.
Furthermore, the relation between NT-pro-BNP and all-cause
death was independent of baseline co-morbidity, as similar HRs
of all-cause death were found in subgroups of patients with
and without CHF [HRCHF 1.26 (1.13–1.41); HRnoCHF 1.27
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Table 2 Risk of all-cause death, combined cardiovascular endpoint, myocardial infarction, sudden death, and stroke by
quartiles of baseline N-terminal-pro-B-type-natriuretic-peptide
NT-pro-BNP (pg/mL) Quartile 1  1433
(n 5 313)
Quartile 2 1434–3361
(n 5 312)
Quartile 3 3362–9251
(n 5 312)
Quartile 4  9252
(n 5 312)
All-cause death
Number of events
during study, n
98 136 166 212
Adjusted HR
a (95%
conﬁdence interval)
—
b 1.24 (0.95–1.62), P ¼ 0.116 1.65 (1.27–2.13), P , 0.001 2.06 (1.60–2.67), P , 0.001
Adjusted HR
a (95% conﬁdence interval) with NT-pro-BNP as a continuous variable, 1.27 (1.18–1.36), P , 0.001
Combined cardiovascular endpoint (myocardial infarction, cardiac death, stroke)
Number of events
during study, n
79 106 129 151
Adjusted HR
a (95%
conﬁdence interval)
—
b 1.21 (0.90–1.63), P ¼ 0.206 1.67 (1.25–2.23), P , 0.001 2.00 (1.49–2.67), P , 0.001
Adjusted HR
a (95% conﬁdence interval) with NT-pro-BNP as a continuous variable, 1.24 (1.15–1.34), P , 0.001
Sudden death
Number of events
during study, n
23 37 45 55
Adjusted HR
a (95%
conﬁdence interval)
—
b 1.31 (0.77–2.24), P ¼ 0.319 1.74 (1.04–2.93), P ¼ 0.036 1.98 (1.18–3.32), P ¼ 0.01
Adjusted HR
a (95% conﬁdence interval) with NT-pro-BNP as a continuous variable, 1.28 (1.12–1.47), P , 0.001
Stroke
Number of events
during study, n
11 22 29 37
Adjusted HR
a (95%
conﬁdence interval)
—
b 1.97 (0.94–4.12), P ¼ 0.072 2.74 (1.35–5.58), P ¼ 0.005 4.13 (2.03–8.39), P , 0.001
Adjusted HR
a (95% conﬁdence interval) with NT-pro-BNP as a continuous variable, 1.39 (1.17–1.65), P , 0.001
Myocardial infarction
Number of events
during study, n
47 48 51 54
Adjusted HR
a (95%
conﬁdence interval)
—
b 0.93 (0.62–1.40), P ¼ 0.729 1.14 (0.76–1.72), P ¼ 0.525 1.23 (0.80–1.88), P ¼ 0.350
Adjusted HR
a (95% conﬁdence interval) with NT-pro-BNP as a continuous variable, 1.08 (0.96–1.22), P ¼ 0.219
aAdjustment for gender, age, treatment, phosphate, low-density lipoprotein, haemoglobin, glycated haemoglobin, albumin, smoking, systolic/diastolic blood pressure, body mass
index, ultraﬁltration volume, duration of dialysis, AV ﬁstula, history of stroke or transitory ischaemic attack, CAD (e.g. MI, coronary artery bypass grafting, percutaneous coronary
intervention, and angiographically documented CAD), peripheral vascular disease, and CHF.
bThe ﬁrst quartile was used as reference for each of the others.
NT-pro-BNP and outcome in haemodialysis 2095(1.15–1.39)] and with and without CAD [HRCAD 1.26 (1.12–
1.42); HRnoCAD 1.28 (1.17–1.40)]. Results of analyses using base-
line NT-pro-BNP as a categorical variable are shown in Figure 1
and Table 2.
Change from baseline
N-terminal-pro-B-type-natriuretic-peptide and the
association with outcome
With rising NT-pro-BNP (continuous variable), the relative risk of
SD, combined CVEs, and all-cause mortality increased signiﬁcantly,
although no signiﬁcant association with the risk of stroke or
MI was detected. These results were independent of baseline
NT-pro-BNP, as analyses stratiﬁed by baseline levels (less than
or equal to and greater than the median) showed a similar
pattern. Furthermore, the increasing risk of death with rising
NT-pro-BNP was independent of baseline co-morbidity (CHF
and CAD).
Results of analyses using the change from baseline NT-pro-BNP
as a categorical variable are shown in Figure 2 and Table 3. Patients
with more than a doubling in NT-pro-BNP had a 51% higher risk
of SD, a 37% higher risk of CVEs, and a 46% higher risk of all-cause
death than patients with stable levels. Regarding SD, further sub-
group analysis showed that patients with low baseline NT-pro-BNP
(less than or equal to the median) and a subsequent increase of
.100% exhibited a more than three-fold increase in the risk of
SD (HR 3.51, 95% CI 1.20–10.27) compared with patients with
stable levels. Accordingly, the relative risk of SD was more than
halved in patients with baseline NT-pro-BNP above the median
and a subsequent decrease .10% (HR 0.42, 95% CI 0.23–0.76)
compared with patients with stable NT-pro-BNP.
Discussion
This study investigated the association of two consecutive
NT-pro-BNP measurements with the outcome in a large
prospective patient cohort with a high incidence of pre-speciﬁed
and centrally adjudicated endpoints during 4 years of follow-up.
In patients with T2DM on haemodialysis, baseline NT-pro-BNP
was a risk factor for SD, stroke, CVEs, and all-cause mortality. In
addition, the increase in NT-pro-BNP during follow-up was associ-
ated with SD, CVEs, and all-cause mortality. Notably, neither
baseline nor change from baseline NT-pro-BNP was associated
with MI.
Few data exist that speciﬁcally focus on NT-pro-BNP and the
risk of SD. Only one study in heart failure patients has investigated
this association before.
12 Against this background, the present
analysis adds important new information to current knowledge
when demonstrating a clear association between baseline
NT-pro-BNP and risk of SD. This might have been due to the
high incidence of SD in the present analysis (n ¼ 160) and the
long follow-up period of 4 years compared with the former one
(n ¼ 44, 1.68 years). Moreover, the follow-up measurement
allowed for identifying subgroups of patients at higher and lower
risk. In addition to the consistently high risk of patients with
increasing NT-pro-BNP, subgroup analysis in patients with high
baseline NT-pro-BNP showed a lower adjusted relative risk of
SD for those with decreasing NT-pro-BNP (.10% decrease) com-
pared with patients with stable levels. Since SD is common in
patients with T2DM on haemodialysis (60% of cardiovascular and
26% of all-cause death) and mortality is high, NT-pro-BNP might
be useful in risk stratiﬁcation when considering therapeutic inter-
ventions (e.g. more frequent dialysis, beta-blocker, implantable
cardioverter deﬁbrillator).
13,14
In contrast to patients with normal renal function, the associ-
ation between stroke and NT-pro-BNP has not been evaluated
in patients with kidney disease.
4,15–17 We found that baseline
NT-pro-BNP was a risk factor for stroke, although the change in
NT-pro-BNP had no signiﬁcant effect on the occurrence of cer-
ebrovascular events. The association of NT-pro-BNP and stroke
was independent of anaemia
18 and arrhythmia, but we did not
Figure 2 Kaplan–Meier estimates for time to sudden death, cardiovascular event (cardiac death, non-fatal myocardial infarction, or stroke),
and all-cause mortality in subgroups of patients according to change from baseline N-terminal-pro-B-type-natriuretic-peptide (group 1: less
than –10%; group 2: –10 up to þ10%; group 3: .10 up to 100%; and group 4: .100%).
K. Winkler et al. 2096adjust for lesion size, insular involvement, or stroke severity, which
were shown to eliminate NT-pro-BNP from a multivariate model
in patients with acute stroke.
19
Limited data have been reported about NT-pro-BNP and MI in
patients with stable vascular disease.
20 As Omland et al.,
20 we
found no association between NT-pro-BNP and MI, and further-
more found that changes in NT-pro-BNP did not affect the risk
of MI, independently of baseline NT-pro-BNP levels. This suggests
that the association between NT-pro-BNP and mortality as well as
combined CVEs was unlikely to be explained by the risk of MI.
By now, follow-up measurements of NT-pro-BNP in chronic
vascular disease and their association with various endpoints
have not been reported in this form. The increase in NT-pro-BNP
from baseline (continuous variable) was associated with an
increased risk of combined CVEs and mortality, independent of
baseline NT-pro-BNP and—regarding the risk of death—indepen-
dent of baseline co-morbidity (history of CHF or CAD). In cate-
gorized analysis, the increase .100% was associated with a
higher risk of outcome compared with patients with stable levels
(NT-pro-BNP+10% from baseline), whereas smaller increases
(,100%) or decreases (.10%) in NT-pro-BNP had no signiﬁcant
effect on outcome.
As other investigators,
1–4,7–9 we found baseline NT-pro-BNP
to be a risk factor for all-cause mortality. The HR for mortality
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Table 3 Change from baseline N-terminal-pro-B-type-natriuretic-peptide and risk of all-cause death, combined
cardiovascular events, myocardial infarction, sudden death, and stroke
Per cent change from baseline NT-pro-BNP (pg/mL)
Decrease (less than 210%)
(n 5 428)
No change
(210 to 10%)
(n 5 160)
Increase (>10–100%)
(n 5 352)
Increase (>100%)
(n 5 263)
All-cause death
Number of events
during study, n
183 71 163 167
Adjusted HR
a (95%
conﬁdence interval)
0.90 (0.68–1.19), P ¼ 0.454 —
b 0.99 (0.74–1.31), P ¼ 0.931 1.46 (1.10–1.95), P ¼ 0.009
Adjusted HR
a (95% conﬁdence interval) with NT-pro-BNP as a continuous variable, 1.23 (1.14–1.34), P , 0.001
Combined cardiovascular endpoint (myocardial infarction, cardiac death, stroke)
Number of events
during study, n
144 52 117 110
Adjusted HR
a (95%
conﬁdence interval)
1.00 (0.72–1.38), P ¼ 0.996 —
b 0.98 (0.70–1.36), P ¼ 0.898 1.37 (0.98–1.92), P ¼ 0.068
Adjusted HR
a (95% conﬁdence interval) with NT-pro-BNP as a continuous variable, 1.19 (1.07–1.32), P ¼ 0.001
Sudden death
Number of events
during study, n
39 23 37 53
Adjusted HR
a (95%
conﬁdence interval)
0.61 (0.36–1.02), P ¼ 0.060 —
b 0.70 (0.42–1.19), P ¼ 0.192 1.51 (0.91–2.51), P ¼ 0.109
Adjusted HR
a (95% conﬁdence interval) with NT-pro-BNP as a continuous variable, 1.45 (1.25–1.69), P , 0.001
Stroke
Number of events
during study, n
32 12 26 18
Adjusted HR
a (95%
conﬁdence interval)
0.88 (0.45–1.73), P ¼ 0.706 —
b 0.91 (0.45–1.83), P ¼ 0.790 0.96 (0.45–2.02), P ¼ 0.908
Adjusted HR
a (95% conﬁdence interval) with NT-pro-BNP as a continuous variable, 1.10 ( 0.89–1.37), P ¼ 0.391
Myocardial infarction
Number of events
during study, n
69 19 51 41
Adjusted HR
a (95%
conﬁdence interval)
1.30 (0.78–2.18), P ¼ 0.319 —
b 1.14 (0.69–1.95), P ¼ 0.630 1.35 (0.77–2.36), P ¼ 0.290
Adjusted HR
a (95% conﬁdence interval) with NT-pro-BNP as a continuous variable, 1.08 ( 0.92–1.26), P ¼ 0.380
aAdjustment for gender, age, treatment, phosphate, low-density lipoprotein, haemoglobin, glycated haemoglobin, albumin, ever smoking, systolic/diastolic blood pressure, body
mass index, ultraﬁltration volume, duration of dialysis, AV ﬁstula, history of stroke or transitory ischaemic attack, CAD (e.g. MI, coronary artery bypass grafting, percutaneous
coronary intervention, and angiographically documented CAD), peripheral vascular disease, and CHF.
bThe group with no change (i.e. a change of 210 to 10%) was used as reference for each of the others.
NT-pro-BNP and outcome in haemodialysis 2097(HRfourth vs. ﬁrst quartile 2.06; 95% CI 1.60–2.67) was lower than that
observed in peritoneal dialysis patients
7 (HR 4.97; 95% CI 1.35–
18.28) and patients from the Ludwigshafen Risk and Cardiovascular
Health Study without kidney disease
3 (HR 3.8; 95% CI 1.99–7.28).
This might be due to the high mortality in the present patient
cohort. After a follow-up period of 4 years, the cumulative rate
of death in patients with NT-pro-BNP  400 and ,2000 pg/mL
was 0.34, and that in patients with NT-pro-BNP .2000 pg/mL
was 0.57. In individuals from the Ludwigshafen Risk and Cardiovas-
cular Health Study,
3 the respective values were 0.12 and 0.29. As
overall mortality was remarkably lower in the latter cohort, the
relative risk of dying could be considerably higher. However,
further comparisons were impeded by varying categorizations of
NT-pro-BNP, follow-up time, etc. As NT-pro-BNP in other
studies equally affected cardiovascular morbidity and hypervolae-
mia, it remains speculative whether optimal adjustment of dry
weight might inﬂuence prognosis.
9,21
Similar to other patients with chronic kidney disease, baseline
NT-pro-BNP (median 3361 pg/mL) largely exceeded normal
values (,50–334 pg/mL)
7–9,22,23 in the present study. According
to a previous work, left ventricular wall tension,
24 associated
haemodynamic factors,
5–7,25 cardiac ischaemia,
26,27 and reduced
renal extraction
22,23,28 are possible causative factors. In addition,
NT-pro-BNP was shown to depend on volume status and residual
diuresis in haemodialysis patients
9,21 and to be higher in diabetic
patients.
29 In the present study, baseline data seem to be well com-
patiblewiththis.However,thepercentageofpatientswithAVﬁstula
potentially causing a volume overload was lowest in patients with
NT-pro-BNP levels in the fourth quartile. This was against expec-
tations since the creation of an AV ﬁstula was shown to produce
an elevation of BNP.
30,31 In the present study, median NT-pro-BNP
increased slightly over time, possibly reﬂecting a progression of
disease. A similar increase is known from patients at high risk of
major vascular events from the Heart Protection Study, where sim-
vastatin effectively improved outcome, and patients on simvastatin
showed less increase in NT-pro-BNP compared with the placebo
group.
16 In the present study, baseline, post-baseline, and change
in NT-pro-BNP levels between atorvastatin- and placebo-treated
patients did not differ signiﬁcantly.
Our study has certain limitations. It is a post hoc analysis within a
selected cohort of German patients with T2DM on haemodialysis.
Therefore, the relationship between NT-pro-BNP and risk may
not be generalizable. We did not analyse heart failure events
because of their low incidence and because they (except for
death due to heart failure) have not been pre-speciﬁed endpoints.
Although preliminary observations in this data set suggest that the
concentrations of NT-pro-BNP are independent of the haemodia-
lysis ultraﬁltration volume, a more in-depth analysis as to whether
intensive haemodialysis would reduce NT-pro-BNP and thus
potentially attenuate risk would be desirable.
In summary, NT-pro-BNP is an important risk factor for death
and CVEs in patients with T2DM on maintenance haemodialysis
treatment. Not only high baseline NT-pro-BNP but also increases
in NT-pro-BNP over time are associated with poor long-term clini-
cal outcome. Whether treatment strategies guided by
NT-pro-BNP levels will decrease morbidity and mortality needs
to be evaluated in future.
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The above article uses a new reference style being piloted by the
EHJ that shall soon be used for all articles.
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